Sinobiopharma, Xianfeng Partner To Manufacture, Co-Promote Clindamycin, Lalanyl-L-glutamine

Sinobiopharma and Xianfeng said that Clindamycin is an antibiotic used to treat anaerobic bacterial infections. It can also be used to treat some protozoal diseases, such as malaria. It is a common topical treatment for acne and can be useful against some methicillin-resistant bacteria.

Whereas, L-alanyl-L-glutamine is a parenteral nutrition prescribed for patients following surgery.

As per the terms of the agreement, Xianfeng is expected to pay Sinobiopharma for access to the technologies, wherein Sinobiopharma will pay Xianfeng for manufacturing the drugs. Additionally, Sinobiopharma and Xianfeng are expected to jointly market the products.

Sinobiopharma said that it owns the drug certificates, drug registration approval documents and production technologies of Clindamycin and L-alanyl-L-glutamine.

Lequn Lee Huang, chairman and CEO of Sinobiopharma, said: “Xianfeng has the GMP-certified facilities for the production of Clindamycin and L-alanyl-L-glutamine and is a strong marketing partner. We expect production to start later this year and are confident this cooperation will help fuel the continued growth of Sinobiopharma.”